88 - Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination: a pooled analysis

Thursday, October 17, 2024

10:42 AM – 10:54 AM US PT

Location: 411

Presenting Author(s)

HL

Heidi Leister-Tebbe, BSN (she/her/hers)

Clinician/Clinical Lead
Pfizer Inc
Collegeville, Pennsylvania, United States
WB

Weihang Bao, PhD

Pfizer Inc
New York, New York, United States
RQ

Romina Quercia, M.D., Ph.D.

Pfizer
London, England, United Kingdom
Jennifer Hammond, PhD

Head of Antiviral Development
Pfizer Inc
Collegeville, PA, United States

Disclosure(s):

John M. McLaughlin, PhD: Pfizer: Employee, Stocks/Bonds (Public Company)

Heidi Leister-Tebbe, BSN: Pfizer Inc: Employee, Stocks/Bonds (Public Company)

Weihang Bao, PhD: Pfizer: Employee, Stocks/Bonds (Public Company)

Romina Quercia, M.D., Ph.D.: Pfizer: Employee, Stocks/Bonds (Public Company)

Jennifer Hammond, PhD: Pfizer, Inc: Employee, Stocks/Bonds (Public Company)